Xoma Corp XOMA
We take great care to ensure that the data presented and summarized in this overview for XOMA Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XOMA
View all-
Bvf Inc San Francisco, CA2.98MShares$74.1 Million2.61% of portfolio
-
Morgan Stanley New York, NY1.12MShares$27.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY512KShares$12.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA459KShares$11.4 Million0.0% of portfolio
-
Opaleye Management Inc. Boston, MA253KShares$6.29 Million1.39% of portfolio
-
Geode Capital Management, LLC Boston, MA187KShares$4.64 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA169KShares$4.19 Million0.02% of portfolio
-
State Street Corp Boston, MA145KShares$3.6 Million0.0% of portfolio
-
Stonepine Capital Management, LLC Bend, OR130KShares$3.23 Million2.52% of portfolio
-
Tls Advisors LLC Miami, FL119KShares$2.96 Million5.36% of portfolio
Latest Institutional Activity in XOMA
Top Purchases
Top Sells
About XOMA
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Insider Transactions at XOMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 21
2025
|
Barbara Kosacz |
BUY
Grant, award, or other acquisition
|
Direct |
11,942
+50.0%
|
-
|
|
May 21
2025
|
Heather L Franklin |
BUY
Grant, award, or other acquisition
|
Direct |
5,971
+50.0%
|
-
|
|
May 21
2025
|
Natasha Hernday |
BUY
Grant, award, or other acquisition
|
Direct |
5,971
+39.87%
|
-
|
|
May 21
2025
|
Matthew D Perry |
BUY
Grant, award, or other acquisition
|
Direct |
5,971
+20.03%
|
-
|
|
May 21
2025
|
Jack L Wyszomierski |
BUY
Grant, award, or other acquisition
|
Direct |
5,971
+24.4%
|
-
|
|
May 20
2025
|
Thomas M. Burns SVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
10,482
-31.72%
|
$262,050
$25.38 P/Share
|
|
May 20
2025
|
Owen Hughes Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,637
-29.02%
|
$640,925
$25.38 P/Share
|
|
May 19
2025
|
Thomas M. Burns SVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,773
+34.97%
|
-
|
|
May 19
2025
|
Owen Hughes Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
53,359
+37.66%
|
-
|
|
May 16
2025
|
Bvf Partners L P > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
392,723
-13.05%
|
$10,603,521
$27.1 P/Share
|
|
Apr 07
2025
|
Bradley Sitko Chief Investment Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+28.39%
|
$48,000
$24.7 P/Share
|
|
Apr 07
2025
|
Joseph M Limber |
BUY
Open market or private purchase
|
Direct |
5,243
+34.4%
|
$131,075
$25.6 P/Share
|
|
Apr 04
2025
|
Joseph M Limber |
BUY
Open market or private purchase
|
Direct |
3,346
+41.29%
|
$83,650
$25.56 P/Share
|
|
Apr 04
2025
|
Joseph M Limber |
BUY
Open market or private purchase
|
Direct |
3,476
+14.81%
|
$86,900
$25.25 P/Share
|
|
Apr 03
2025
|
Joseph M Limber |
BUY
Open market or private purchase
|
Direct |
1,411
+50.0%
|
$35,275
$25.44 P/Share
|
|
Apr 03
2025
|
Joseph M Limber |
BUY
Open market or private purchase
|
Direct |
16,524
+50.0%
|
$413,100
$25.22 P/Share
|
|
Apr 01
2025
|
Thomas M. Burns SVP, Finance & CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+33.33%
|
$25,000
$25.46 P/Share
|
|
Mar 31
2025
|
Bradley Sitko Chief Investment Officer |
BUY
Open market or private purchase
|
Direct |
245
+7.45%
|
$6,125
$25.39 P/Share
|
|
Mar 31
2025
|
Bradley Sitko Chief Investment Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+8.01%
|
$19,000
$19.98 P/Share
|
|
Mar 21
2025
|
Bradley Sitko Chief Investment Officer |
BUY
Open market or private purchase
|
Direct |
2,800
+50.0%
|
$70,000
$25.43 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 35.8K shares |
|---|---|
| Exercise of conversion of derivative security | 142K shares |
| Open market or private purchase | 39.2K shares |
| Open market or private sale | 1.11M shares |
|---|